BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 24928190)

  • 1. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
    Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
    Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
    Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
    Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug interactions with solid tumour-targeted therapies.
    Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of targeted anticancer therapy.
    Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
    Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
    Terada T; Noda S; Inui K
    Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving towards dose individualization of tyrosine kinase inhibitors.
    Klümpen HJ; Samer CF; Mathijssen RH; Schellens JH; Gurney H
    Cancer Treat Rev; 2011 Jun; 37(4):251-60. PubMed ID: 20833478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
    J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
    Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
    Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
    Henriksen JN; Andersen CU; Fristrup N
    Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic issues on cancer pharmacotherapy].
    Tanigawara Y
    Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
    Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
    Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
    Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
    Mueller-Schoell A; Groenland SL; Scherf-Clavel O; van Dyk M; Huisinga W; Michelet R; Jaehde U; Steeghs N; Huitema ADR; Kloft C
    Eur J Clin Pharmacol; 2021 Apr; 77(4):441-464. PubMed ID: 33165648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma.
    Liao D; Shangguan D; Yao D; Zhu Q; Cao L; Long M; Wu Y; Xiang D; Yang N
    Protein Pept Lett; 2018; 25(6):528-533. PubMed ID: 29848258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
    Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
    Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Personalized medicine for oral molecular-targeted anticancer drugs].
    Miura M
    Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
    Oude Munnink TH; Henstra MJ; Segerink LI; Movig KL; Brummelhuis-Visser P
    Clin Pharmacol Ther; 2016 Apr; 99(4):419-31. PubMed ID: 26265133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.